PDCD1 and neoplasm: Both radiotherapy and certain cytotoxic agents can promote immunogenic cell death, upregulate tumor antigen presentation, and increase PD-L1 expression, providing a strong biological rationale for combining NACRT with PD-1 blockade (11, 12).